E7B6 peptide epitope (E7B6) (E7B6)

The E7B6 peptide epitope is a specific amino acid sequence derived from the human nuclear autoantigen La/SS-B, serving as the extracellular recognition component of the Reverse Chimeric Antigen Receptor (RevCAR) platform (Mitwasi et al., 2020). In this innovative modular design, T-cells are engineered to express the E7B6 peptide on their surface, which acts as a universal docking site for therapeutic intervention. Activation of these RevCAR-E7B6 T-cells is strictly dependent on the administration of a bispecific Target Module (TM), which bridges the T-cell to a tumor cell by binding both the E7B6 epitope and a specific tumor-associated antigen, such as CD123 or PSMA (Feldmann et al., 2020). This architecture allows for a switchable and tunable immune response, where the intensity of T-cell activity can be controlled by the dosage of the TM, potentially reducing the risk of severe adverse events. The use of a human-derived, typically intracellular epitope like E7B6 minimizes the risk of spontaneous T-cell activation against healthy tissues and provides a versatile scaffold for developing multi-specific logic-gated therapies (Kittel-Boselli et al., 2021).

Other names

La-E7B6 epitope7B6 epitopeLa-derived peptide tagSS-B peptide epitope

The E7B6 peptide epitope functions as a molecular bridge in the RevCAR system; it is expressed on the T-cell surface and is targeted by a bispecific Target Module (TM) that simultaneously binds a tumor antigen, thereby inducing T-cell activation and directed tumor cell lysis.